Wockhardt receives USFDA approval for generic version of Parkinsons drug Requip XL

28 Aug 2012 Evaluate

Wockhardt has received USFDA approval for marketing generic version of 2mg, 4mg, 6mg, 8mg & 12 mg extended-release tablets containing Ropinirole Hydrochloride, which is used in the treatment of Parkinson's disease. Roinirole extended release tablet is the generic name for the brand Requip XL, marketed in the US by Glaxo SmithKline. The company would be launching the product as soon as possible.

In the US generic pharmaceutical market, Workhardt has been consistently growing maket shares for all its products. In many instance, Workhardt, by virtual of amongst the few players to market technically challenging product has reaped the advantage of being an early entrant

Wockhardt will be manufacturing the extended release tablets of Ropinirole at its facility in at Aurangabad India. The technology for the tables was developed in-house.

According to IMS Health, the total market for this product in the US is about $58 million and the incidence of Parkinson's disease has been increasing worldwide.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1230.95 58.60 (5.00%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.